June 26, 2017 08:30 AM EDT

Matinas Bio shares are crushed on disappointing PhII antifungal data

John Carroll

Editor & Founder

Shares of Matinas BioPharma $MTNB were shredded early Monday after the biotech announced that its lead anti-infectives program failed to match a mainstay in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Matinas Bio shares are crushed on disappointing PhII antifungal data

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

We’re about to find out which RFK Jr. will show up at HHS

Astellas shakes up management despite impressive nine-month earnings

Illumina added to China's blacklist following Biosecure Act, tariffs

Mati­nas Bio shares are crushed on dis­ap­point­ing PhII an­ti­fun­gal da­ta

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Matinas Bio shares are crushed on disappointing PhII antifungal data